Comparative Pharmacology
Head-to-head clinical analysis: DUREZOL versus EYSUVIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUREZOL versus EYSUVIS.
DUREZOL vs EYSUVIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing immune cell migration and cytokine release.
Eysuvis (loteprednol etabonate ophthalmic suspension) is a corticosteroid that works by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes, thereby reducing inflammation.
1 drop of 0.1% ophthalmic solution in the affected eye(s) four times daily for up to 14 days.
1 drop in each eye twice daily (approximately 12 hours apart) for 4 weeks.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours in adults; prolonged to 24–36 hours in hepatic impairment.
Approximately 2-4 hours for loteprednol etabonate; clinical effect correlates with dosing interval (e.g., 4 times daily).
Renal excretion of unchanged drug accounts for 30% of clearance; biliary/fecal elimination accounts for 60%, with the remainder as metabolites.
Primarily renal (90-95% as unchanged drug and metabolites); minor biliary/fecal (<5%).
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid